DaVita Inc. $DVA Shares Purchased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its holdings in DaVita Inc. (NYSE:DVA) by 132.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 264,084 shares of the company’s stock after purchasing an additional 150,318 shares during the period. Arrowstreet Capital Limited Partnership owned approximately 0.37% of DaVita worth $37,619,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Dynamic Technology Lab Private Ltd purchased a new stake in shares of DaVita in the 1st quarter valued at $364,000. Edgestream Partners L.P. purchased a new position in DaVita during the 2nd quarter valued at about $6,375,000. LPL Financial LLC grew its position in DaVita by 36.2% in the 1st quarter. LPL Financial LLC now owns 18,689 shares of the company’s stock valued at $2,859,000 after acquiring an additional 4,968 shares in the last quarter. Sovran Advisors LLC purchased a new stake in DaVita during the second quarter worth about $472,000. Finally, Caxton Associates LLP acquired a new stake in shares of DaVita during the first quarter worth about $513,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DVA. Zacks Research upgraded shares of DaVita from a “strong sell” rating to a “hold” rating in a report on Friday, November 28th. Wall Street Zen cut shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Cowen reaffirmed a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Monday. Finally, TD Cowen lowered their target price on DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a research note on Monday, November 3rd. Six research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $148.00.

DaVita Price Performance

DaVita stock opened at $117.41 on Friday. The stock has a market cap of $8.29 billion, a PE ratio of 12.09, a P/E/G ratio of 0.88 and a beta of 1.00. The stock’s fifty day moving average is $123.67 and its two-hundred day moving average is $132.88. DaVita Inc. has a 1-year low of $113.97 and a 1-year high of $179.60.

DaVita (NYSE:DVA) last released its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The business had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.43 billion. During the same quarter in the previous year, the company posted $2.59 EPS. The company’s revenue was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.